On October 1, 2021 IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, reported that a poster describing translational data obtained in the DeCidE clinical study in patients with advanced, recurrent ovarian cancer will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 10-14, 2021 in Washington, DC (Press release, IMV, OCT 1, 2021, sec.gov/Archives/edgar/data/1734768/000117625621000258/exhibit99-1.htm [SID1234590623]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title: Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer

Presenter:

Oliver Dorigo, M.D., Ph.D.,
Director and Associate Professor
Division Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University, CA
Poster Number: 353

Important dates

November 9, 2021: Full abstracts are made public at 8 a.m. EST

November 12, 2021: Poster presentation

Poster Hall Hours: 7 a.m.–8:30 p.m.

Dr. Dorigo will be present in person at lunch time (12:40–2:10 p.m. EST) and during the poster reception (7–8:30 p.m. EST)

November 12, 2021: Poster and e-poster presentation will be available under the Scientific Publications & Posters section on IMV’s website.

On October 1, 2021 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, reported four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36TH Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021 (Press release, Nkarta, OCT 1, 2021, View Source [SID1234590616]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The full abstracts are scheduled to be available on the SITC (Free SITC Whitepaper) website on November 9, 2021.

Presented jointly with CRISPR Therapeutics:

Title:
A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
Abstract Number and Type:
16439, oral*
Poster Presentation Date and Time:
November 10, 2021, 2:40 p.m. ET

Title:
CISH Gene-knockout Anti-CD70-CAR NK Cells Demonstrate Potent Anti-tumor Activity Against Solid Tumor Cell Lines and Provide Partial Resistance to Tumor Microenvironment Inhibition
Abstract Number and Type:
113, poster
Poster Presentation Date and Time:
November 12, 2021, 7:00 am – 8:30 pm ET

Nkarta presentations:

Title:
Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application
Abstract Number and Type:
151, poster
Poster Presentation Date and Time:
November 12, 2021, 7:00 am – 8:30 pm ET

Title:
KIR Haplotype Can Inform Donor Selection in the Production of Allogeneic Memory-Like CAR NK Cells for Clinical Application
Abstract Number and Type:
128, poster
Poster Presentation Date and Time:
November 13, 2021, 7:00 am – 8:30 pm ET

* View Source; a
pre-conference program; additional registration is required.

On October 1, 2021 Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, reported the upcoming presentation of data on its neoantigen DNA cancer vaccine platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2021 (Press release, ImmuneTune, OCT 1, 2021, View Source [SID1234590615]). The submitted abstract was selected for a poster presentation during the SITC (Free SITC Whitepaper) conference, taking place virtually and physically in Washington, D.C., from November 10 – 14, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The selected abstract is titled "Personalized synthetic polyepitope DNA cancer vaccines encoding a novel pyroptotic adjuvant to generate effective anti-tumor T cell immunity". Abstracts can be accessed on the SITC (Free SITC Whitepaper) website once the conference begins on November 9; posters will be presented on November 12 and 13.

"It is an exciting opportunity to present our latest preclinical data at a leading international scientific and medical conference. Building upon our publication in the journal OncoImmunology in 2019, these data now include the combination of our synthetic, linear DNA cancer vaccine platform with a novel adjuvant that targets pyroptosis to elicit a potent T cell response against tumor-specific neoantigens," stated Jeroen van Bergen, CSO of Immunetune, and presenter of the poster at SITC (Free SITC Whitepaper).

On October 1, 2021 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that the permanent J-code for COSELA (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (CMS) is now effective for provider billing for all sites of care (Press release, G1 Therapeutics, OCT 1, 2021, View Source [SID1234590614]). The permanent J-code for COSELA, J1448 (Injection, trilaciclib, 1mg.), published online on the CMS website here (page 5).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J-codes are permanent, product specific reimbursement codes assigned to outpatient and physician administered "buy and bill" products under Medicare Part B and are used by commercial insurers and government payers to facilitate and standardize claims submissions and reimbursements for medications like COSELA. With the permanent J-code now in effect, all hospital outpatient departments, ambulatory surgery centers and physician offices in the United States will have one consistent Healthcare Common Procedure Coding System (HCPCS) code to standardize the submission and payment of COSELA insurance claims across Medicare, Medicare Advantage, Medicaid and commercial plans.

"Given the emergent presentation of extensive-stage small cell lung cancer, and the clinical benefits of COSELA as a proactive multilineage myeloprotection drug when give prior to chemotherapy, it is absolutely essential that patients have timely access to it," said Jack Bailey, Chief Executive Officer of G1 Therapeutics. "We are pleased to receive this new permanent J-code for all sites of care as it will enable a more efficient billing process, which will ultimately help facilitate patient access to COSELA."

G1’s new technology add-on payment (NTAP) for COSELA which provides additional payment to inpatient hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount also became effective for provider billing today, October 1, 2021.

About COSELA (trilaciclib) for Injection

COSELA (trilaciclib) was approved by the U.S. Food and Drug Administration on February 12, 2021.

Indication
COSELA (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

Important Safety Information
COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib.

Warnings and precautions include injection-site reactions (including phlebitis and thrombophlebitis), acute drug hypersensitivity reactions, interstitial lung disease (pneumonitis), and embryo-fetal toxicity.

The most common adverse reactions (>10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

This information is not comprehensive. Please click here for full Prescribing Information. View Source

On October 1, 2021 Juntendo University (President: Hajime Arai, M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that the parties have established, inside Juntendo University Graduate School of Medicine, a joint research course entitled, "Direct Reprogramming Regenerative Medicine Course" （Professor & Director, Diagnostics and Therapeutics of Interactable Diseases, Intractable Disease Research Center, Genome Medical Center: Yasushi Okazaki M.D., Ph.D., Specially Appointed Professor: Masahito Matsumoto, Ph.D.） (Press release, Astellas, OCT 1, 2021, View Source [SID1234590612]). The course will be retained for a term of three years from October 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This joint research course aims to create a new modality that maximizes the therapeutic effect for diseases with high unmet medical needs, such as type 1 diabetes, by direct reprogramming using the K factor*1 . Itwill also conduct research to expand this modality to other diseases. Juntendo University Graduate School of Medicine will be acquiring the basic data including the study of the optimal combination of direct reprogramming factors that include the K factor, and Astellas will be conducting the applied research for disease treatment by gene therapy using this factor and selection of the optimal modality.

Direct reprogramming is a biology that directly converts the fate of cells without passing through the pluripotent state. The technology that enables direct reprogramming in vivo has attracted attention as a new regenerative medicine technology. Unlike conventional therapies, direct reprogramming not only removes unwanted cells or replenishes necessary cells; it also converts unnecessary cells into necessary cells. It is therefore expected to show high efficacy against intractable diseases that have been thought to be incurable.

Juntendo University and Astellas have been conducting joint research collaboration on the establishment of differentiation methods for therapeutic cells by direct reprogramming based on the agreement executed in 2018. This time, as part of this joint research collaboration, the two parties have established this joint research course to further strengthen the partnership and progressively conduct research on direct reprogramming as a new therapeutic paradigm.

Through this joint research course, Juntendo University and Astellas will take on the challenge of drug discovery based on direct reprogramming technology, with the aim of providing patients with new treatment options.